InvestorsHub Logo
Followers 120
Posts 9122
Boards Moderated 0
Alias Born 07/17/2005

Re: deri21 post# 8973

Tuesday, 06/18/2013 12:21:00 PM

Tuesday, June 18, 2013 12:21:00 PM

Post# of 64409
I received the news by email alert, but so far it hasn't shown up in any of my accounts--Etrade, Fidelity or Schwab. The product is an excellent one and those who have tried it love it because it means they will be able to control their pain without having to be dependent on prescription opiate pain meds.

I mean, what if Pfizer or another big guy wanted Nyloxin to add to its own product offerings? Pfizer paid $3.6 billion or $14.25 per share to acquire King Pharmaceuticals, mostly for its pain medication products. NPHC seems undervalued to the EXTREME.

"Big drug companies have sought to strike mergers to strengthen their product lineups as patents expire, in what analysts have called a “patent cliff.”

http://dealbook.nytimes.com/2010/10/12/pfizer-to-buy-king-pharmaceuticals-for-3-6-billion/